TOP TEN perturbations for 38495_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38495_s_at
Selected probe(set): 214088_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38495_s_at (214088_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-3.9602804Number of Samples:8 / 18
| Experimental | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2
Relative Expression (log2-ratio):-3.421507Number of Samples:2 / 2
| Experimental | keratinocyte differentiation study 2 (KLF4 siRNA) |
| KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency. | |
| Control | keratinocyte differentiation study 2 |
| Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):2.9858408Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)
Relative Expression (log2-ratio):-2.9022474Number of Samples:34 / 19
| Experimental | diabetes type 2 study 27 (LCM) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year. | |
| Control | diabetes type 2 study 27 (enzymatic) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies. |
Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1
Relative Expression (log2-ratio):2.89472Number of Samples:17 / 8
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):2.8667946Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
psoriasis study 25 (lesional; baseline; ustekinumab; responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)
Relative Expression (log2-ratio):2.7298641Number of Samples:22 / 23
| Experimental | psoriasis study 25 (lesional; baseline; ustekinumab; responder) |
| Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. | |
| Control | psoriasis study 25 (non-lesional; baseline; ustekinumab; responder) |
| Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT. |
psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)
Relative Expression (log2-ratio):2.7220497Number of Samples:22 / 23
| Experimental | psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) |
| Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. | |
| Control | psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder) |
| Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT. |
psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Relative Expression (log2-ratio):2.6800385Number of Samples:10 / 9
| Experimental | psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) |
| Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. | |
| Control | psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder) |
| Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT. |
psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Relative Expression (log2-ratio):-2.6700926Number of Samples:18 / 22
| Experimental | psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder) |
| Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 90 mg ustekinumab and assigned as responders. Ustekinumab was administered subcutaneously in dose of 90 mg at week 0 and 4. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code: | |
| Control | psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) |
| Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. |